Be extremely careful taking @SeekingAlpha bios/articles at face value. For example, this guy Zhiyuan Sun, @Woodrow8664, who writes glowingly of , claims to be CFO of a Fintech, and a former hedge fund manager. 
I can't find any record of Tatry Capital L.P. ever having existed on Google or sec.gov. And the "fintech" is "a student run startup." (side note: hello Utah)
This author has more than 1,000 followers, has published extensively on @SeekingAlpha Pro, and yet his writing contains massive factual errors that should not have passed even cursory editing. Take this article on :
Here Zhiyuan Sun states that FT-218 has a "40% inferior" AUC (area under the curve) to Xyrem, noting "total absorption of 2.3 vs 3.8 on the dose response curve [sic]."
If you click on the studies he cites, however, you'd see that they show the AUCinf of FT-218 is nearly equal to that of Xyrem.
The 2.3 (FT-318) vs 3.8 (Xyrem) numbers he references actually pertain to "dose proportionality," i.e. when you increase the dose, how much does the AUC increase. A number closer to 1 is better here, because it implies more predictable clearance/drug levels.
TL;DR: self-proclaimed "hedge fund manager" and "biotech contributor" Zhiyuan Sun is spouting misinformation on @SeekingAlpha, to a large audience, with inadequate editorial control.
